迈微医疗完成亿元级融资，专注于心血管多模态治疗技术

Core Insights - Maiwei Medical has successfully completed a Series A+ financing round, raising over 1 billion RMB, led by Yuanhe Origin with participation from Zhengxin Valley Capital and existing shareholders Tianfeng Capital and Waterwood Venture [1] - The funds will be primarily used to accelerate the commercialization of its core product, the NxPFA® nanosecond pulsed electric field ablation system, and to advance the development of comprehensive cardiac electrophysiology solutions based on nsPFA technology [1] - Maiwei Medical focuses on innovative medical devices for cardiovascular multimodal treatment, having developed multiple innovative products and solutions for conditions such as atrial fibrillation and resistant hypertension since its establishment in July 2021 [1] Product Development - The NxPFA® nanosecond pulsed electric field ablation system is expected to receive approval from the National Medical Products Administration (NMPA) by July 2025, becoming the world's first and only approved nsPFA product, marking a significant advancement in the field [1] - In the field of hypertension intervention, Maiwei Medical's muRDN™ ultrasound renal denervation system has entered the registration verification phase after successfully enrolling its first patient in the ModulationHTN-2 multicenter clinical study in June 2025 [2] - The muRDN system, along with the NxPFA® system, aims to create a "heart-kidney interaction" intervention loop, enhancing the management of atrial fibrillation and hypertension, and contributing to a strategic upgrade towards comprehensive cardiovascular management for millions of patients globally [2]